Top 5 Takeaways Expanded Indication: The FDA expanded the use of recombinant zoster vaccine (RZV) to include immunocompromised adults aged ≥19 years. ACIP Recommendation: ACIP recommends two doses of RZV
Category: MMWR Booster
Top 5 Takeaways Prevalence of Birth Defects: Approximately 5% of infants in the U.S. Zika Pregnancy and Infant Registry (USZPIR) had Zika-associated brain or eye defects. Common Defects: Frequently reported
Top 5 Takeaways Significant Increase in Overdose Deaths: Drug overdose deaths in the U.S. increased by 28.5% from April 2020 to April 2021. Emergence of Para-fluorofentanyl: Para-fluorofentanyl, a substance from
Top 5 Takeaways Third Dose Effectiveness: A third dose of mRNA vaccines was highly effective at preventing COVID-19–associated emergency department (ED) and urgent care (UC) encounters and hospitalizations during both
Top 5 Takeaways Omicron Predominance: By late December 2021, the Omicron variant became the predominant strain in the U.S., leading to a surge in COVID-19 cases, ED visits, and hospitalizations.
Top 5 Takeaways Vaccine Effectiveness: COVID-19 vaccines remained highly effective against hospitalization and death, even with the emergence of the Delta variant and waning immunity. Impact of Booster Doses: Booster
Top 5 Takeaways New Vaccine Recommendations: The Advisory Committee on Immunization Practices (ACIP) now recommends the use of either the 15-valent PCV (PCV15) or the 20-valent PCV (PCV20) for adults
Top 5 Takeaways Highest Risk Group: Unvaccinated individuals without a previous COVID-19 diagnosis had the highest rates of COVID-19 cases and hospitalizations. Impact of Delta Variant: After the Delta variant
Top 5 Takeaways Higher Vaccination Coverage Among Gay or Lesbian Adults: Gay or lesbian adults reported higher COVID-19 vaccination coverage (85.4%) compared to heterosexual adults (76.3%). Gender Differences in Vaccination:
Top 5 Takeaways Increased Vaccine Effectiveness: A third dose of mRNA COVID-19 vaccines significantly increased vaccine effectiveness (VE) against hospitalization from 82% to 97% in immunocompetent adults and from 69%